This is an A-1 revision of a competing continuation application for DK55023 which has been active for the past 10 years, and which has served as the basis for the PI's exploration of growth factor, signaling and cell cycle control in the pancreatic beta cell. It is now clear that both Type 1 as well as Type 2 diabetes result in part or entirely from beta cell deficiency and/or dysfunction, and that beta cell replacement can reverse diabetes in humans. The two major hurdles to beta cell replacement and regeneration are now an incomplete ability to prevent auto- and allo-immune attack, and a grossly inadequate supply of human beta cells. This renewal application addresses the second hurdle. While it is now abundantly clear that it is possible to activate rodent beta cell replication, human beta cells remain refractory to replication induced by growth factors, nutrients, and signaling pathway activation. Our group has characterized the murine and human beta cell cycle control machinery and has developed cell-cycle based approaches to driving robust human beta cell replication. In this application, we describe studies focused on three interesting and surprising cell cycle regulators that have emerged from prior versions of this grant: p57, cMyc and p107. Most investigators would not intuitively have selected these three as likely candidates for normal cell cycle control and human beta cell expansion. We believe that the data presented herein move them from among the least interesting to among the most interesting and potentially important candidates for regulating beta cell proliferation in rodents and humans. Thus, the Specific Aims of this proposal are:
Specific Aim 1. To Define the Importance of p57 in Restraining Rodent and Human Beta Cell Replication.
Specific Aim 2. To Define the Pathophysiology and Therapeutic Potential of Mild, Graded and Transient cMyc Overexpression in Rat and Human Beta Cells.
Specific Aim 3. To Define the Relevance of the Pocket Protein, p107, in Mouse and Human Beta Cell Cycle Repression. These studies should provide important insight into how beta cell replication is controlled and lead to insight into how one might develop methods to activate these key molecules in the human beta cell, and permit inducible, regulated human beta cell replication.

Public Health Relevance

Type 1 and Type 2 diabetes have reached epidemic proportions worldwide. A major goal of the NIH and NIDDK is to develop mechanisms to induce human beta cell replication and regeneration in a way that permits retained beta cell function. Whereas it is now relatively easy to induce rodent beta cell replication, human beta cells have proven to be refractory to replication. Thus, a need exists for molecules and pathways that can lead ot human beta cell expansion. In this application, we provide what we believe is compelling evidence that three molecules - p57, cMyc and p107 - are of particular importance in controlling beta cell replication, and describe how they might be manipulated to induce robust and therapeutic human beta cell replication. The studies described herein should shed light on how best to induce therapeutic human beta cell replication and regeneration, whether the ultimate source of beta cells is human cadaveric islets, human embryonic stem cells, induced pluripotent stem cells or porcine islets.

National Institute of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Research Project (R01)
Project #
Application #
Study Section
Cellular Aspects of Diabetes and Obesity Study Section (CADO)
Program Officer
Sato, Sheryl M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Icahn School of Medicine at Mount Sinai
Internal Medicine/Medicine
Schools of Medicine
New York
United States
Zip Code
Bernal-Mizrachi, Ernesto; Kulkarni, Rohit N; Scott, Donald K et al. (2014) Human ?-cell proliferation and intracellular signaling part 2: still driving in the dark without a road map. Diabetes 63:819-31
Bender, Aaron; Stewart, Andrew F (2014) Good news for the ageing beta cell. Diabetologia 57:265-9
Stewart, Andrew F (2014) Betatrophin versus bitter-trophin and the elephant in the room: time for a new normal in ?-cell regeneration research. Diabetes 63:1198-9
García-Ocaña, Adolfo; Stewart, Andrew F (2014) "RAS"ling ? cells to proliferate for diabetes: why do we need MEN? J Clin Invest 124:3698-700
Fiaschi-Taesch, Nathalie M; Kleinberger, Jeffrey W; Salim, Fatimah G et al. (2013) Human pancreatic *-cell G1/S molecule cell cycle atlas. Diabetes 62:2450-9
Fiaschi-Taesch, Nathalie M; Kleinberger, Jeffrey W; Salim, Fatimah G et al. (2013) Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult human ?-cell replication: a revised model of human ?-cell G1/S control. Diabetes 62:2460-70
Takane, Karen K; Kleinberger, Jeffery W; Salim, Fatimah G et al. (2012) Regulated and reversible induction of adult human ?-cell replication. Diabetes 61:418-24
Karslioglu, Esra; Kleinberger, Jeffrey W; Salim, Fatimah G et al. (2011) cMyc is a principal upstream driver of beta-cell proliferation in rat insulinoma cell lines and is an effective mediator of human beta-cell replication. Mol Endocrinol 25:1760-72
Levitt, H E; Cyphert, T J; Pascoe, J L et al. (2011) Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice. Diabetologia 54:572-82
Fiaschi-Taesch, Nathalie M; Salim, Fatimah; Kleinberger, Jeffrey et al. (2010) Induction of human beta-cell proliferation and engraftment using a single G1/S regulatory molecule, cdk6. Diabetes 59:1926-36

Showing the most recent 10 out of 21 publications